Vanderbilt University Acquires Shares of 14,730 Progyny, Inc. (NASDAQ:PGNY)

Vanderbilt University bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,730 shares of the company’s stock, valued at approximately $254,000.

Several other hedge funds also recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after acquiring an additional 1,526 shares during the period. Mendota Financial Group LLC bought a new position in Progyny during the third quarter valued at about $56,000. Meeder Asset Management Inc. bought a new stake in shares of Progyny in the 3rd quarter worth approximately $77,000. Finally, KBC Group NV raised its stake in Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after acquiring an additional 2,140 shares during the period. 94.93% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Progyny news, Chairman David J. Schlanger acquired 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Anevski bought 209,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the purchase, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by insiders.

Progyny Stock Performance

Progyny stock opened at $22.72 on Thursday. Progyny, Inc. has a one year low of $13.39 and a one year high of $42.08. The company has a 50-day simple moving average of $18.08 and a 200-day simple moving average of $19.05. The firm has a market capitalization of $1.93 billion, a P/E ratio of 39.17, a P/E/G ratio of 2.32 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to analysts’ expectations of $296.85 million. During the same period in the prior year, the company earned $0.16 earnings per share. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. As a group, sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Analysts Set New Price Targets

PGNY has been the subject of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Barclays lowered their price target on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Bank of America decreased their price objective on shares of Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Canaccord Genuity Group lowered their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Finally, Truist Financial reissued a “hold” rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Progyny currently has a consensus rating of “Hold” and an average price target of $25.50.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.